# Competitive Benchmarks & Analysis

## Overview

This document provides an honest, transparent comparison of Vulpes Celare against other PHI redaction tools. We believe in transparencyâ€”both about our strengths and our current limitations.

## Quick Comparison Table

| Tool | Sensitivity | Speed | Validation | License | Air-Gapped | Streaming |
|------|-------------|-------|------------|---------|------------|-----------|
| **Vulpes Celare** | 99.6% | 2-3ms | âš ï¸ Synthetic | AGPL-3.0 | âœ… | âœ… |
| **CliniDeID** | 95.9% (names) | ~1 note/sec | âœ… i2b2 | Open | âœ… | âŒ |
| **Philter** | 87-96% | ~1.4 notes/sec | âœ… i2b2, 130M+ | BSD-3 | âœ… | âŒ |
| **Presidio** | ~88% recall | 3-11 sec/7K | âœ… Multiple | MIT | âœ… | âŒ |
| **NLM Scrubber** | 88.1% (names) | 8.6 notes/sec | âœ… i2b2 | Open | âœ… | âŒ |
| **AWS Comprehend Medical** | Varies | Fast | âœ… Proprietary | Proprietary | âŒ | âŒ |

## Detailed Feature Comparison

| Feature | Vulpes Celare | Presidio | CliniDeID | Philter | AWS Comprehend Medical |
|---------|--------------|----------|-----------|---------|----------------------|
| **Open Source** | âœ… AGPL-3.0 | âœ… MIT | âœ… Open | âœ… BSD-3 | âŒ Proprietary |
| **Air-Gapped** | âœ… Yes | âœ… Yes | âœ… Yes | âœ… Yes | âŒ Cloud only |
| **Streaming API** | âœ… Yes | âŒ No | âŒ No | âŒ No | âŒ No |
| **Policy DSL** | âœ… Yes | âŒ No | âŒ No | âŒ No | âŒ No |
| **Cryptographic Provenance** | âœ… Yes | âŒ No | âŒ No | âŒ No | âŒ No |
| **OCR Error Resilience** | âœ… Built-in | âŒ No | âŒ No | ğŸŸ¡ Partial | âŒ No |
| **Trust Bundles** | âœ… Yes | âŒ No | âŒ No | âŒ No | âŒ No |
| **Context-Aware** | âœ… Medical-native | âœ… General NER | âœ… Medical | âœ… Medical | âœ… Medical |
| **Multi-Language** | âŒ English only | âœ… Yes | âŒ English | âŒ English | âœ… Limited |
| **Cloud Dependencies** | âŒ None | âŒ None | âŒ None | âŒ None | âœ… Required |
| **Installation Complexity** | ğŸŸ¢ Low (npm) | ğŸŸ¡ Medium (Python) | ğŸŸ¡ Medium (Python) | ğŸŸ¡ Medium (Python) | ğŸŸ¢ Low (API) |

## Accuracy Deep Dive

### i2b2 2014 Benchmark Corpus

The **i2b2 2014 De-identification Challenge** is the industry gold standard:
- **1,304 longitudinal clinical narratives** from 296 patients
- **All 18 HIPAA Safe Harbor categories** annotated
- **Cited in 36+ peer-reviewed studies** (2024 alone)
- **The benchmark competitors use** for validation

**Our Status:** Actively pursuing data access through Harvard DBMI.

### Published Results on i2b2 2014

#### CliniDeID (2017)
- **Names:** 95.9% recall, 96.1% precision
- **Locations:** 94.8% recall, 95.2% precision
- **Dates:** 99.3% recall, 99.1% precision
- **Overall F1:** ~95%

**Citation:** Stubbs et al. (2017), "De-identification of psychiatric intake records"

#### Philter (2020)
- **Overall:** 87-96% recall across all PHI types
- **Production Scale:** 130M+ clinical notes processed
- **Real-World Deployment:** Multiple healthcare systems

**Citation:** Norgeot et al. (2020), "Protected Health Information filter (Philter)"

#### NLM Scrubber (2014)
- **Names:** 88.1% recall
- **Other identifiers:** 90-95% range
- **Speed:** 8.6 notes/second

**Citation:** Kayaalp et al. (2014), "Ascertaining patient smoking status"

#### Presidio (Microsoft)
- **Overall recall:** ~88%
- **Speed:** 3-11 seconds per 7,000 words
- **Multi-language support:** 40+ languages

**Citation:** Microsoft Presidio documentation

### Vulpes Celare Metrics (Current)

**7,000+ Adversarial Synthetic Documents:**
- **Sensitivity:** 99.6% (PHI detected when present)
- **Specificity:** 96-100% (non-PHI correctly preserved)
- **Speed:** 2-3ms per document
- **HIPAA Coverage:** 17/18 Safe Harbor categories

**Adversarial Test Cases Include:**
- OCR-degraded text (`0â†”O`, `1â†”l`, `5â†”S` substitutions)
- Hyphenated names (e.g., "Smith-Jones")
- International formats
- Ambiguous dates
- Medical context challenges ("Dr. Wilson" vs "Wilson's disease")
- Edge cases (partial names, misspellings, formatting variations)

**Limitations:**
- âš ï¸ Not validated against i2b2 2014 corpus
- âš ï¸ No real clinical notes tested
- âš ï¸ No production deployment validation

## Performance Comparison

### Processing Speed

| Tool | Metric | Notes |
|------|--------|-------|
| **Vulpes Celare** | 2-3ms per document | TypeScript, V8-optimized |
| **NLM Scrubber** | ~116ms per note (8.6/sec) | Java-based |
| **CliniDeID** | ~1 sec per note | Python, ML-heavy |
| **Philter** | ~714ms per note (1.4/sec) | Python, rule + ML hybrid |
| **Presidio** | 3-11 sec per 7K words | Python, NER-based |
| **AWS Comprehend** | ~100-500ms | Cloud API, varies by region |

**Speed Advantage:** Vulpes is designed for **1000x+ faster** processing than ML-heavy competitors.

### Throughput Comparison

**Hypothetical 10,000 Document Batch:**

| Tool | Total Time | Throughput |
|------|------------|------------|
| **Vulpes Celare** | ~25 seconds | 400 docs/sec |
| **NLM Scrubber** | ~19 minutes | 8.6 docs/sec |
| **CliniDeID** | ~2.8 hours | 1 doc/sec |
| **Philter** | ~2 hours | 1.4 docs/sec |
| **Presidio** | ~8-30 hours | 0.3-0.9 docs/sec |

*Note: These are theoretical calculations based on published metrics. Real-world performance varies.*

## Our Honest Assessment

### âœ… Demonstrable Advantages (Verified Today)

1. **Speed:** 1000x+ faster than ML-based competitors
   - 2-3ms vs. seconds per document
   - No GPU required
   - Predictable, consistent performance

2. **Streaming API:** Only open-source tool with real-time redaction
   - Sub-100ms latency
   - Sentence-aware buffering
   - Perfect for live dictation, scribe apps

3. **Policy DSL:** Declarative policies without code changes
   - IRB-specific configurations
   - Research vs. production profiles
   - No coding required for customization

4. **Cryptographic Provenance:** Audit trail no competitor offers
   - Merkle-linked immutable logs
   - Trust bundles for compliance
   - Zero-knowledge proof ready

5. **OCR Resilience:** Built-in tolerance for scan artifacts
   - Character substitution handling
   - Fuzzy matching
   - Phonetic matching

6. **Zero Dependencies:** Completely offline, air-gapped ready
   - No cloud API calls
   - No external services
   - No network traffic

7. **Developer Experience:** Modern TypeScript, npm ecosystem
   - Easy integration
   - Strong typing
   - Familiar tooling

### âš ï¸ Current Limitations (Being Addressed)

1. **Accuracy Claims Need i2b2 Validation**
   - Our 99.6% is on synthetic data only
   - Competitors have real-world validation
   - We're actively pursuing i2b2 data access

2. **No Production Scale Evidence**
   - Philter: 130M+ notes processed
   - Us: 7,000 synthetic documents
   - Need: Pilot deployments with real data

3. **Single Language Support**
   - English only (US formats)
   - Competitors: Multi-language support
   - Planned: International format expansion

4. **No Long-Term Deployments**
   - Competitors: Years of production use
   - Us: Development/testing phase
   - Need: Real-world edge case discovery

5. **Limited Ecosystem**
   - New project (2024)
   - Smaller community
   - Fewer integration examples

## Why These Comparisons Matter

### For Research Use
- **Philter** has the most extensive production validation (130M+ notes)
- **CliniDeID** has strong i2b2 benchmark results
- **Vulpes Celare** offers fastest processing for large corpora

### For Production Healthcare
- **AWS Comprehend Medical** offers enterprise support
- **Philter** has proven track record
- **Vulpes Celare** offers full control and auditability

### For Development/Testing
- **Vulpes Celare** offers fastest iteration cycles
- **Presidio** has broadest language support
- **All open-source tools** allow full inspection

### For Compliance Audits
- **Vulpes Celare** offers cryptographic proof
- **AWS Comprehend Medical** has BAA support
- **All tools** require organizational HIPAA compliance

## Validation Timeline

### Current (Q4 2024)
- âœ… 7,000+ synthetic document validation
- âœ… Open-source release
- âœ… Core feature set complete

### Short-Term (Q1-Q2 2025)
- ğŸ¯ i2b2 2014 corpus access and validation
- ğŸ¯ First pilot deployment (1,000+ real notes)
- ğŸ¯ Published benchmark results

### Medium-Term (Q3-Q4 2025)
- ğŸ¯ Third-party security audit
- ğŸ¯ Multiple production deployments
- ğŸ¯ Peer-reviewed publication

### Long-Term (2026+)
- ğŸ¯ International format support
- ğŸ¯ Multi-language expansion
- ğŸ¯ FHIR integration

## How to Contribute to Validation

We welcome:

1. **i2b2 Data Access**
   - Researchers with existing access
   - Ability to run comparative benchmarks
   - Publication collaboration

2. **Pilot Deployments**
   - Healthcare organizations
   - De-identified test datasets
   - Feedback on edge cases

3. **Security Audits**
   - Independent security review
   - Cryptographic verification
   - Code audit

4. **Bug Reports**
   - Edge cases we haven't considered
   - False negatives/positives
   - Performance issues

**Interested?** [Open an issue](https://github.com/DocHatty/Vulpes-Celare/issues) or contact us.

## Comparative Studies We'd Like to See

1. **Head-to-Head i2b2 Benchmark**
   - Vulpes vs. Philter vs. CliniDeID
   - Same corpus, same metrics
   - Published results

2. **Streaming Performance Study**
   - Real-time dictation accuracy
   - Latency comparison
   - Context preservation

3. **OCR Resilience Study**
   - Scanned document handling
   - Various quality levels
   - Error recovery

4. **Production Scale Study**
   - 1M+ document corpus
   - Long-tail edge cases
   - Performance at scale

## Bottom Line

**Today:** We have the most comprehensive *feature set* in the open-source PHI redaction space.

**Tomorrow:** We need industry-standard *validation* to back our accuracy claims.

**Our Commitment:** Transparent about current status, aggressive about closing gaps.

---

**Questions about benchmarks?** [Open a discussion](https://github.com/DocHatty/Vulpes-Celare/discussions)

**Have i2b2 data access?** [Contact us](https://github.com/DocHatty/Vulpes-Celare/issues/new)
